Floatz logo

Tabelecleucel

EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)

Pierre Fabre MedicamentCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD) cohort.

Asset / SponsorPhaseRating
Valganciclovir
Viracta Therapeutics, Inc.
Phase 2B
METHOTREXATE
University of Miami
Phase 2CCC
Hydroxyurea
University of Miami
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Miami
Phase 2CCC
Arginine Butyrate
HemaQuest Pharmaceuticals Inc.
Phase 2CCC

View all 17 →

Same molecule, other indications

Tabelecleucel is also rated in:

Solid Organ Transplant ComplicationsDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →